Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer
Open Access
- 1 September 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Oncology
- Vol. 21 (5), 469-474
- https://doi.org/10.1097/cco.0b013e32832d56e4
Abstract
Traditional morphologically based imaging modalities are now being complemented by positron emission tomography (PET)/computed tomography (CT) in prostate cancer. Metastatic prostate cancer is an attractive target for radioimmunotherapy (RIT) as no effective therapies are available. This review highlights the most important achievements within the last year in PET/CT and RIT of prostate cancer. Conflicting results exist on the use of choline for detection of malignant disease in the prostate gland. The role of PET/CT in N-staging remains to be elucidated further. However, 18F-choline and 11C-choline PET/CT have been demonstrated to be useful for detection of recurrence. 18F-choline and 18F-fluoride PET/CT are useful for detection of bone metastases. Prostate tumor antigens may be used as targets for RIT. Prostate-specific membrane antigen is currently under focus of a number of diagnostic and therapeutic strategies. J591, a monoclonal antibody, which targets the extracellular domain of prostate-specific membrane antigen, shows promising results. HER2 receptors may also have a potential as target for PET/CT imaging and RIT of advanced prostate cancer. PET/CT in prostate cancer has proven to play a significant role, in particular for detection of prostate cancer recurrence and bone metastases. RIT of metastatic prostate cancer warrants further investigations.Keywords
This publication has 54 references indexed in Scilit:
- Changes inHER2Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and18F-Labeled Affibody MoleculesJournal of Nuclear Medicine, 2009
- Biodistributions of 177Lu- and 111In-Labeled 7E11 Antibodies to Prostate-Specific Membrane Antigen in Xenograft Model of Prostate Cancer and Potential Use of 111In-7E11 as a Pre-therapeutic Agent for 177Lu-7E11 RadioimmunotherapyMolecular Imaging & Biology, 2008
- C-11 Choline PET/CT Imaging for Differentiating Malignant From Benign Prostate LesionsClinical Nuclear Medicine, 2008
- [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancerNuclear Medicine and Biology, 2008
- Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y RadioimmunotherapyJournal of Nuclear Medicine, 2008
- Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold MoleculesJournal of Nuclear Medicine, 2008
- HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer AgentsJournal of Liposome Research, 2008
- [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- 18F-Fluoride Positron Emission Tomography and Positron Emission Tomography/Computed TomographySeminars in Nuclear Medicine, 2007
- Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate CancerClinical Cancer Research, 2007